Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use PRADAXA Oral Pellets safely and effectively. See full prescribing information for PRADAXA Oral Pellets. PRADAXA® (dabigatran etexilate) oral pellets Initial U.S. Approval: 2010
Medication labelWhy this: Advisory · dailymed-prescription
PRADAXA Oral Pellets are indicated for the treatment of venous thromboembolic events (VTE) in pediatric patients aged 3 months to less than 12 years of age who have been treated with a parenteral anticoagulant for at least 5 days. PRADAXA Oral Pellets are indicated to reduce the risk of recurrence of VTE in pediatric patients aged 3 months to less than 12 years of age who have been previously treated.
- generic_name
- dabigatran etexilate
- product_names
- dabigatran etexilate
- ndc
- 0597-0425, 0597-0430, 0597-0435, 0597-0440, 0597-0445, 0597-0450, 0597-0425-78, 0597-0430-18, 0597-0435-96, 0597-0440-53, 0597-0445-87, 0597-0450-16
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en